HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minoxidil Plus product seizure Aug. 3 is latest action in long-running case of Upjohn v. Medtron.

Executive Summary

MINOXIDIL PLUS PRODUCT SEIZURE AUG. 3 IN NEW YORK CITY is the latest action in a long-running legal effort by Upjohn to bar a Manhattan salon from capitalizing on Rogaine labeling for treatment of hair loss. The seizure of "Minoxidil Plus" came after Manhattan federal court Judge Shirley Wohl Kram ruled July 19 that the Hair & Skin Treatment Center (formerly New York Hair Labs, formerly Medtron) was in contempt of the court's 1990 and 1992 injunctions enjoining the defendant from the "manufacturing, sale, distribution, advertisement, and promotion" of products covered by Upjohn's Rogaine patents.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS026691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel